Adhera Therapeutics Stock Price, News & Analysis
Company Description
Adhera Therapeutics (OTC Link: ATRX) is a publicly traded biotechnology company in the Healthcare sector. The company has a market capitalization of $72.2K.
On a trailing twelve-month basis, Adhera Therapeutics reported net income of -$2.1M.
This page provides a comprehensive overview of ATRX stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Adhera Therapeutics (ATRX) stock last traded at $0.0001. At a market capitalization of $72.2K, ATRX is classified as a micro-cap stock with approximately 7.2M shares outstanding.
Latest News
Adhera Therapeutics has 10 recent news articles. Of the recent coverage, 6 articles coincided with positive price movement and 2 with negative movement. Key topics include clinical trial, management, acquisition. View all ATRX news →
SEC Filings
Financial Highlights
operating income reached -$1.6M, and net income was -$2.1M. The company generated -$1.4M in operating cash flow. With a current ratio of 0.00, short-term liquidity bears monitoring.
Upcoming Events
Short Interest History
Days to Cover History
ATRX Company Profile & Sector Positioning
Adhera Therapeutics (ATRX) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the OTC Link.
Investors comparing ATRX often look at related companies in the same sector, including GB Sciences (GBLX), U S Stem Cell Inc (USRM), Reneuron Group (RNUGF), Syros Pharmaceut (SYRS), and Aridis Pharmaceuticals Inc (ARDS). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate ATRX's relative position within its industry.